Bluebird, cleared for Zynteglo launch, aims to dose first patients soon

Bluebird Bio CEO snares $24 million pay package as gene therapy advance
Weeks after it was cleared to launch in Germany, the first Zynteglo patients could be treated in the next few months. (Bluebird)

Dogged for months by concerns over manufacturing, Bluebird Bio's ultra-pricey flagship gene therapy Zynteglo was finally cleared for launch in Germany just weeks ago. Now, with a manufacturing green light in hand, Bluebird is hoping to make good on its commercial hopes in the coming months. 

Bluebird plans to dose its first commercial patients for Zynteglo in Germany in the first half of the year, the drugmaker said Tuesday.

In late January, Bluebird said the European Medicines Agency approved the “refined commercial drug product manufacturing specifications for Zynteglo," giving the drug the all-clear to launch in Germany. Bluebird has yet to seek FDA approval for the treatment.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Zynteglo, approved as a one-time treatment for patients 12 and over with transfusion-dependent beta-thalassemia, is Bluebird's first approved drug, though the CAR-T prospect it shares with Bristol-Myers Squibb, Ide-cel, is inching toward the finish line. The drugmaker pulled in $10 million in the fourth quarter in license and royalty revenues from that collaboration.

RELATED: Bluebird Bio readies Zynteglo launch as EU approves 'refined' manufacturing

RELATED: Bluebird Bio delays Zynteglo launch as manufacturing trips up another gene therapy

Bluebird has priced Zynteglo in Europe at €1.575 million ($1.77 million), a cost that is amortized over five years and paid only if it works on patients treated for transfusion-dependent beta-thalassemia. Bluebird previously said it planned to file its FDA application for Zynteglo by year-end 2019, but it has yet to send the therapy to U.S. regulators. 

The drug is being manufactured in Europe by Apceth Biopharma, whose CEO Christine Guenther said the CDMO was “in the final stages of preparing to manufacture a cell-based gene therapy for commercial use.”

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.